ArticleEuropean journal of nuclear medicine and molecular imaging2018
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.Frontiers in oncology · 2021Pooled it
- Baseline Ga-68 PSMA PET/CT-derived volumetric parameters as predictors of biochemical recurrence following radical prostatectomy.Annals of nuclear medicine · 2026Article
- Article
- PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Biodistribution and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Article
- Role ofBMC cancer · 2025Article
- Diagnostic value ofCancer biology & therapy · 2024Article
- Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?Annals of nuclear medicine · 2024Article
- An Automated Deep Learning-Based Framework for Uptake Segmentation and Classification on PSMA PET/CT Imaging of Patients with Prostate Cancer.Journal of imaging informatics in medicine · 2024Article
- Whole-body tumour burden on [18F]DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics.European journal of nuclear medicine and molecular imaging · 2024Article
- Pre-treatmentMolecular imaging and biology · 2024Article
- Deep learning-based whole-body characterization of prostate cancer lesions on [European journal of nuclear medicine and molecular imaging · 2024Article
- The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [Breast cancer research : BCR · 2024Article
- Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens.Diagnostics (Basel, Switzerland) · 2024Review
- Theranostics and artificial intelligence: new frontiers in personalized medicine.Theranostics · 2024Review
- Early biochemical and radiographic response after one cycle of [European journal of nuclear medicine and molecular imaging · 2023Article
- Evaluation of a convolution neural network for baseline total tumor metabolic volume on [European radiology · 2023Article
- Quantitative assessment of PSMA PET response to therapy in castration-sensitive prostate cancer using an automated imaging platform for disease identification and measurement.European journal of hybrid imaging · 2023Article
- Automated quantification of PET/CT skeletal tumor burden in prostate cancer using artificial intelligence: The PET index.European journal of nuclear medicine and molecular imaging · 2023Article
- Analysis of interreader agreement in structured reports of pelvic multiparametric magnetic resonance imaging using the METastasis Reporting and Data System for Prostate Cancer guidelines.Diagnostic and interventional radiology (Ankara, Turkey) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed at evaluating the role of
methodsA total of 142 patients with biochemical recurrence of prostate cancer underwent PET/CT with [
resultsPSMA-TV and TL-PSMA demonstrated a significant correlation with serum PSA levels (P < 0.0001) and TL-PSMA was significantly different for different Gleason scores. The agreement rate between TL-PSMA derived from PET and biochemical response was 87% (95% confidence interval, 0.66-0.97; Cohen's κ = 0.78; P < 0.01) and, thus, higher than for SUVmax, which was 74% (95% CI, 0.52-0.90; κ = 0.55; P < 0.01). Furthermore, agreement with PSA was higher for TL-PSMA and SUVmax than for CT-based response evaluation. Discordant findings between PET and CT were most likely due to limitations of CT and RECIST in rating small lymph nodes as metastases, as well as bone involvement, which was sometimes not detectable in CT.
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.